FORTRESS BIOTECH INC (FBIO) Stock Fundamental Analysis
USA - NASDAQ:FBIO - US34960Q3074 - Common Stock
2.67 USD
+0.06 (+2.3%)
2.65 USD
-0.02 (-0.75%)
We assign a fundamental rating of 2 out of 10 to FBIO. FBIO was compared to 533 industry peers in the Biotechnology industry. FBIO has a bad profitability rating. Also its financial health evaluation is rather negative. FBIO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
FBIO had negative earnings in the past year.
FBIO had a negative operating cash flow in the past year.
FBIO had negative earnings in each of the past 5 years.
FBIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of FBIO (-15.04%) is better than 81.05% of its industry peers.
With a decent Return On Equity value of -54.76%, FBIO is doing good in the industry, outperforming 63.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.04% | ||
| ROE | -54.76% | ||
| ROIC | N/A |
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FBIO has a Gross Margin of 70.91%. This is amongst the best in the industry. FBIO outperforms 81.80% of its industry peers.
FBIO's Gross Margin has declined in the last couple of years.
FBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
2. Health
2.1 Basic Checks
FBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FBIO has more shares outstanding
FBIO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for FBIO is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -7.51, we must say that FBIO is in the distress zone and has some risk of bankruptcy.
FBIO has a Altman-Z score of -7.51. This is in the lower half of the industry: FBIO underperforms 67.73% of its industry peers.
FBIO has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of FBIO (1.14) is worse than 78.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.51 |
ROIC/WACCN/A
WACC10.42%
2.3 Liquidity
FBIO has a Current Ratio of 1.92. This is a normal value and indicates that FBIO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.92, FBIO is doing worse than 76.92% of the companies in the same industry.
FBIO has a Quick Ratio of 1.70. This is a normal value and indicates that FBIO is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.70, FBIO is not doing good in the industry: 79.55% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.7 |
3. Growth
3.1 Past
FBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.37%, which is quite impressive.
Looking at the last year, FBIO shows a very negative growth in Revenue. The Revenue has decreased by -31.76% in the last year.
The Revenue has been growing by 9.50% on average over the past years. This is quite good.
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
Revenue 1Y (TTM)-31.76%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%
3.2 Future
FBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.48% yearly.
FBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.44% yearly.
EPS Next Y69.12%
EPS Next 2Y18.7%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue Next Year26.68%
Revenue Next 2Y35.26%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FBIO. In the last year negative earnings were reported.
Also next year FBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.7%
EPS Next 3Y11.48%
5. Dividend
5.1 Amount
FBIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.67
+0.06 (+2.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners16.67%
Inst Owner Change-4.55%
Ins Owners14.9%
Ins Owner Change0.03%
Market Cap79.43M
Revenue(TTM)57.67M
Net Income(TTM)-24.05M
Analysts82.5
Price Target10.71 (301.12%)
Short Float %14.91%
Short Ratio3.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-2.8%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.62%
Min EPS beat(2)-36.17%
Max EPS beat(2)4.93%
EPS beat(4)2
Avg EPS beat(4)-13.52%
Min EPS beat(4)-36.17%
Max EPS beat(4)4.93%
EPS beat(8)6
Avg EPS beat(8)17.06%
EPS beat(12)7
Avg EPS beat(12)9.15%
EPS beat(16)8
Avg EPS beat(16)-15.31%
Revenue beat(2)2
Avg Revenue beat(2)10.78%
Min Revenue beat(2)10.71%
Max Revenue beat(2)10.85%
Revenue beat(4)2
Avg Revenue beat(4)-10.74%
Min Revenue beat(4)-55.48%
Max Revenue beat(4)10.85%
Revenue beat(8)4
Avg Revenue beat(8)13.91%
Revenue beat(12)5
Avg Revenue beat(12)3.45%
Revenue beat(16)7
Avg Revenue beat(16)-0.99%
PT rev (1m)-4.55%
PT rev (3m)-31.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-40%
EPS NY rev (1m)-25.32%
EPS NY rev (3m)29.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.34 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.81 | ||
| P/tB | 5.6 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.62
EYN/A
EPS(NY)-1.93
Fwd EYN/A
FCF(TTM)-3.2
FCFYN/A
OCF(TTM)-2.69
OCFYN/A
SpS1.99
BVpS1.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.04% | ||
| ROE | -54.76% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.91% | ||
| FCFM | N/A |
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score4
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.7 | ||
| Altman-Z | -7.51 |
F-Score4
WACC10.42%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
EPS Next Y69.12%
EPS Next 2Y18.7%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-31.76%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%
Revenue Next Year26.68%
Revenue Next 2Y35.26%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
EBIT growth 1Y-13.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.89%
EBIT Next 3Y5.48%
EBIT Next 5YN/A
FCF growth 1Y43.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.22%
OCF growth 3YN/A
OCF growth 5YN/A
FORTRESS BIOTECH INC / FBIO FAQ
What is the fundamental rating for FBIO stock?
ChartMill assigns a fundamental rating of 2 / 10 to FBIO.
What is the valuation status for FBIO stock?
ChartMill assigns a valuation rating of 0 / 10 to FORTRESS BIOTECH INC (FBIO). This can be considered as Overvalued.
Can you provide the profitability details for FORTRESS BIOTECH INC?
FORTRESS BIOTECH INC (FBIO) has a profitability rating of 2 / 10.
How sustainable is the dividend of FORTRESS BIOTECH INC (FBIO) stock?
The dividend rating of FORTRESS BIOTECH INC (FBIO) is 0 / 10 and the dividend payout ratio is -2.8%.